Related Experiment Video
Updated: Jul 16, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Tumor suppressor p53 mediates interleukin-6 expression to enable cancer cell evasion of genotoxic stress
Trinh T T Phan1, Nam V Truong2, Wen-Guey Wu2
1Institute of Molecular and Cellular Biology, College of Life Sciences and Medicine, National Tsing Hua University, Hsinchu, 300044, Taiwan ROC.
Abstract:
The tumor suppressor p53 primarily functions as a mediator of DNA damage-induced cell death, thereby contributing to the efficacy of genotoxic anticancer therapeutics. Here, we show, on the contrary, that cancer cells can employ genotoxic stress-induced p53 to acquire treatment resistance through the production of the pleiotropic cytokine interleukin (IL)-6. Mechanistically, DNA damage, either repairable or irreparable, activates p53 and stimulates Caspase-2-mediated cleavage of its negative regulator mouse double minute 2 (MDM2) creating a positive feedback loop that leads to elevated p53 protein accumulation. p53 transcriptionally controls the major adenosine triphosphate (ATP) release channel pannexin 1 (Panx1), which directs IL-6 induction via a mechanism dependent on the extracellular ATP-activated purinergic P2 receptors as well as their downstream intracellular calcium (iCa2+)/PI3K/Akt/NF-ĸB signaling pathway. Thus, p53 silencing impairs Panx1 and IL-6 expression and renders cancer cells sensitive to genotoxic stress. Moreover, we confirm that IL-6 hampers the effectiveness of genotoxic anticancer agents by mitigating DNA damage, driving the expression of anti-apoptotic Bcl-2 family genes, and maintaining the migratory and invasive properties of cancer cells. Analysis of patient survival and relevant factors in lung cancer and pan-cancer cohorts supports the prognostic and clinical values of Panx1 and IL-6. Notably, IL-6 secreted by cancer cells during genotoxic treatments promotes the polarization of monocytic THP-1-derived macrophages into an alternative (M2-like) phenotype that exhibits impaired anti-survival activities but enhanced pro-metastatic effects on cancer cells as compared to nonpolarized macrophages. Our study reveals the precise mechanism for genotoxic-induced IL-6 and suggests that targeting p53-mediated IL-6 may improve the responsiveness of cancer cells to genotoxic anticancer therapy.
Insights
Cancer cells use DNA damage-induced p53 to resist treatment via interleukin-6 (IL-6) production. Targeting this p53-IL-6 pathway may enhance genotoxic cancer therapy effectiveness.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- The tumor suppressor p53 is crucial for DNA damage-induced cell death, enhancing genotoxic cancer therapy.
- Cancer cells can develop resistance to genotoxic stress, limiting therapeutic efficacy.
Purpose of the Study:
- To elucidate the mechanism by which cancer cells acquire resistance to genotoxic stress via p53.
- To investigate the role of interleukin-6 (IL-6) in mediating this resistance.
- To explore the prognostic and therapeutic implications of the p53-IL-6 pathway in cancer.
Main Methods:
- Investigated p53-mediated IL-6 production in response to DNA damage.
- Utilized molecular biology techniques to analyze signaling pathways including Caspase-2, MDM2, Panx1, and purinergic receptors.
- Assessed the impact of p53 and IL-6 on cancer cell sensitivity to genotoxic agents.
- Analyzed patient survival data from lung cancer and pan-cancer cohorts.
- Examined the effect of cancer-derived IL-6 on macrophage polarization.
Main Results:
- Genotoxic stress activates p53, leading to increased IL-6 production through a feedback loop involving Caspase-2, MDM2, and pannexin-1 (Panx1).
- p53-mediated IL-6 production confers resistance to genotoxic therapy by reducing DNA damage, upregulating anti-apoptotic genes, and promoting cell migration.
- Silencing p53 or Panx1 restores cancer cell sensitivity to genotoxic stress.
- Elevated Panx1 and IL-6 levels correlate with poorer patient survival in lung and pan-cancer cohorts.
- Cancer-derived IL-6 promotes M2-like macrophage polarization, enhancing pro-metastatic effects.
Conclusions:
- Cancer cells exploit DNA damage-induced p53 to produce IL-6, mediating treatment resistance.
- The p53-Panx1-IL-6 axis is a key mechanism driving genotoxic therapy resistance and influencing cancer progression.
- Targeting the p53-mediated IL-6 pathway presents a potential strategy to improve the efficacy of genotoxic anticancer therapies.
Related Concept Videos
Abnormal Proliferation
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
DNA Damage can Stall the Cell Cycle
Negative Regulator Molecules
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

